icon-folder.gif   Conference Reports for NATAP  
 
  EASL 44th Annual Meeting
April 22-26, 2009
Copenhagen, Denmark
Back grey_arrow_rt.gif
 
 
 
Abbott/Enanta - Potent HCV Protease Inhibitors with the Potential for Once-daily Dosing and Broad Genotype Coverage
 
 
  EASL
Reported by Jules Levin
 
L. J. Jiang, Y. Gai, T. Middleton*, K. Kurtz*, L. Lu*, S. Liu, T. Phan, X. Luo, T. Poon, B. Brasher, K. McDaniel*, D. Kempf* and Y. S. Or
 
Enanta Pharmaceuticals, Inc.
*Abbott Laboratories
 
From Jules: Abbott has an ambitious HCV drug program that includes polymerase inibitors and protease inhibitors. The Abbott/Enanta protease inhibitor preclinical data presented at EASL show them to be potent and with potential capacity to reach high levels. The data finds the PIs to be active against key HCV mutations suggesting perhaps antiviral activity against HCV resistance to other protease inhibitors, but of course this would have to be established in patients but would of particular appeal.

Background-1.gif

across-2.gif

EC-3.gif

index-4.gif

po-5.gif

rat-6.gif

dosing-7.gif